anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A fluid composition for the eradication of head lice comprises an insecticide, characterised in that the composition includes at least one substituted or unsubstituted diloxane as the insecticide. The siloxane may be a linear compound, a cyclic compound or a block copolymer. If the cyclic siloxane is substituted it may have four to six siloxy residues in the ring but if it is unsubstituted it may have at least five siloxy residues in the ring. The siloxanes may be a mixture of linear siloxanes and cyclosiloxanes. Preferably the fluid composition also contains dissolved or dispersed dimethiconal (present from 0.1 to 15 percent by volume).  The fluid may also contain less that three percent by weight of an analgesic(eg camomile essence), an antiseptic (eg lavender oil), an anti-inflammatory and/or a repellent (eg feverfew essence) composition; preferably the amount is less than one percent by weight. The fluid may contain at least one oil selected from the group containing cedarwood oil, clove oil, geranium oil, lavender oil, lemon oil, eucalyptus oil and rosemary oil. The fluid may comprise from 85 to 99.9 percent by volume of the substituted or unsubstituted cyclosiloxanes. Preferably the fluid comprises 95.5 to 97.5 percent by volume cyclopenta-siloxane and 2.5 to 4.5 percent by volume dimethiconal. The compositions may also be used to eradicate other insects, including arachnids (such as mites).
The present invention relates to a cosmetic composition using an extract obtained by fermenting Curcuma longa (also known as curry) and trifoliate orange. The cosmetic composition can be applied on skin having troubles to eliminate the troubles of the skin. The cosmetic composition includes 0.1-10 wt% of the fermented product of Curcuma longa and trifoliate orange with respect to the total weight of the composition. The present invention aims to provide a cosmetic composition having reduced chemical substances and increased natural materials. The cosmetic composition includes the fermented extract of Curcuma longa and trifoliate orange. Therefore, the cosmetic composition is less irritating to skin, prevents skin from being dry, improves a skin condition, and thus can significantly contribute to improving skin suffering from itch and troubles.
Rich data from large biobanks, coupled with increasingly accessible association statistics from genome-wide association studies (GWAS), provide great opportunities to dissect the complex relationships among human traits and diseases. We introduce BADGERS, a powerful method to perform polygenic score-based biobank-wide association scans. Compared to traditional approaches, BADGERS uses GWAS summary statistics as input and does not require multiple traits to be measured in the same cohort. We applied BADGERS to two independent datasets for late-onset Alzheimer's disease (AD; n=61,212). Among 1738 traits in the UK biobank, we identified 48 significant associations for AD. Family history, high cholesterol, and numerous traits related to intelligence and education showed strong and independent associations with AD. Furthermore, we identified 41 significant associations for a variety of AD endophenotypes. While family history and high cholesterol were strongly associated with AD subgroups and pathologies, only intelligence and education-related traits predicted pre-clinical cognitive phenotypes. These results provide novel insights into the distinct biological processes underlying various risk factors for AD.
The immune response gene 1 (IRG1) and its metabolite itaconate are implicated in modulating inflammation and oxidative stress, with potential relevance to sepsis-induced myocardial dysfunction (SIMD). This study investigates their roles in SIMD using both in vivo and in vitro models. Mice were subjected to lipopolysaccharide (LPS)-induced sepsis, and cardiac function was assessed in IRG1 knockout (IRG1-/-) and wild-type mice. Exogenous 4-octyl itaconate (4-OI) supplementation was also examined for its protective effects. In vitro, bone marrow-derived macrophages and RAW264.7 cells were treated with 4-OI following Nuclear factor, erythroid 2 like 2 (NRF2)-small interfering RNA administration to elucidate the underlying mechanisms. Our results indicate that IRG1 deficiency exacerbates myocardial injury during sepsis, while 4-OI administration preserves cardiac function and reduces inflammation. Mechanistic insights reveal that 4-OI activates the NRF2/HO-1 pathway, promoting macrophage polarization and attenuating inflammation. These findings underscore the protective role of the IRG1/itaconate axis in SIMD and suggest a therapeutic potential for 4-OI in modulating macrophage responses.
Hypothesize, that in patients with on-label osimertinib 1st-line treatment of stage IIIB or IV NSCLC, a biomarker-driven escalation of osimertinib therapy with a platinum-based chemotherapy regimen will effectively enhance PFS and subsequently OS. Lack of EGFRm clearance after an osimertinib treatment period of 3 weeks as assessed by liquid biopsy will be used to predict sub-optimal response. In these patients, treatment will be escalated after approx. 7 weeks of on-label osimertinib monotherapy by adding up to 4 cycles of a combination regimen of pemetrexed and cisplatin or carboplatin. Patients with complete EGFR plasma clearance will continue to receive standard of care osimertinib and will not be eligible for the study. Primary outcome measure will be PFS, which will be compared to historical data on TKI monotherapy from persistent EGFR shedder from the FLAURA trial.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine and concerns a preparations applied for prevention and treatment of disturbed physiological and reparative regeneration of bone tissue and articular cartilage. The composition includes synthetic hydroxyapatite, chitosan gel with bactericidal properties, being a matrix to contain an aqueous solution of preparation "Adgelon", containing serum glycoprotein of the cattle blood. The composition is prepared by mixing hydroxyapatite, chitosan gel with preparation "Adgelon" immobilised on chitosan gel. ^ EFFECT: composition provides improved stimulant property for reparative osteogenesis with restoration of morphologically normal bone matrix. ^ 2 cl, 3 ex
A photochemical method is described for treating atherosclerosis or cancer wherein phycocyanin is injected into a patient suffering from one of these diseases. Once injected, phycocyanin is selectively taken up into atherosclerotic plaques or cancer cells, and upon subsequent irradiation destruction of the atherosclerotic plaques or cancer cells occurs. Phycocyanin offers several advantages over prior art chemicals used for similar purposes. First it is only marginally sensitive to the ultraviolet portion of the spectrum; consequently patients can be irradiated without concern that they will be sensitized to subsequent exposure to sunlight. Second, phycocyanin is selectively taken up into atherosclerotic plaques, with little or no uptake by surrounding normal cells. This ensures that upon subsequent irradiation that the atherosclerotic plaques are selectively destroyed with little or no damage to the surrounding cells or tissue.
This study is to assess whether tranexamic acid (a drug that is used to coagulate the blood and reduce bleeding) use in lumbar spinal fusion can reduce blood loss and postoperative delirium compared to placebo. Thusly reducing need for transfusion, shorting the hospital stay and improving outcomes. For this the study will randomize patients who are receiving elective lumbar interbody fusion (PLIF or TLIF) of 2 or more levels for degenerative disc disease (DDD) into 2 groups. Group 1 would receive tranexamic acid during the surgery while group 2 will receive placebo. Blood loss during the surgery and postoperatively (while the patient has a drain) will be monitored along with the amount of transfusions needed, postoperative cognitive status (including delirium), postoperative markers of systemic inflammation, and and the duration of hospital stay. Delirium occurrence and severity will be assessed daily for the first 5 days after surgery or at discharge, whichever comes first. Cognitive status (neuropsychological tests) will be assessed at post-discharge follow up visits and compared to preoperative status.

The drug or placebo are only given during the surgery. The patient population includes elective cases of patient undergoing lumbar spinal fusion of 2 or more levels. Spinal fusions are known to be associated with blood loss, especially when the surgeries are long and more levels need to be fused.
Malignant ascites accompanied by peritoneal dissemination contain various factors and cell populations as well as cancer cells; however, how the tumor microenvironment is shaped in ascites remains unclear. Single-cell proteomic profiling and a comprehensive proteomic analysis are conducted to comprehensively characterize malignant ascites. Here, we find defects in immune effectors along with immunosuppressive cell accumulation in ascites of patients with gastric cancer (GC) and identify five distinct subpopulations of CD45(-)/EpCAM(-) cells. Mesothelial cells with mesenchymal features in CD45(-)/EpCAM(-) cells are the predominant source of chemokines involved in immunosuppressive myeloid cell (IMC) recruitment. Moreover, mesothelial-mesenchymal transition (MMT)-induced mesothelial cells strongly express extracellular matrix (ECM)-related genes, including tenascin-C (TNC), enhancing metastatic colonization. These findings highlight the definite roles of the mesenchymal cell population in the development of a protumorigenic microenvironment to promote peritoneal dissemination.
Background and Objectives: The interspace between the popliteal artery and the posterior capsule of the knee (iPACK) block has been widely used in perioperative settings to control posterior knee pain and can additionally be used for chronic knee pain. In this cadaveric study, we aimed to investigate the needle tip position and its proximity to the articular branch of the tibial nerve (ABTN) during an iPACK-targeted radiofrequency procedure. Materials and Methods: An ultrasound-guided iPACK block was performed on 20 knees of 10 cadavers. We injected 0.1 mL each of blue and green gelatinous dye near the tibial artery (point A) and posterior knee capsule (point B), respectively, and evaluated the spread of both around the ABTN. For a hypothetical conventional radiofrequency ablation (RFA) lesion (diameter, 2.95 mm) and cooled RFA lesion (diameter, 4.9 mm), we counted the number of specimens in which the ABTNs would be captured. Results: The percentage of specimens in which the ABTN would be captured by a cooled RFA lesion was 64.71% at point A and 43.75% at point B (p = 0.334). Meanwhile, the percentage of specimens in which the ABTN would be captured by a conventional RFA lesion was 58.82% from point A and 25% from point B (p = 0.065). Conclusions: When performing an RFA-based iPACK block, the needle tip may be positioned either lateral to the tibial artery or in the space between the posterior knee capsule and the tibial artery. However, more studies with larger samples are needed to verify these results before the clinical use of this procedure can be recommended.
INTRODUCTION: This paper outlines the design, implementation, and usability study results of the patient empowerment process for chronic disease management, using Patient Reported Outcome Measurements and Shared Decision-Making Processes.
BACKGROUND: The ADLIFE project aims to develop innovative, digital health solutions to support personalized, integrated care for patients with severe long-term conditions such as Chronic Obstructive Pulmonary Disease, and/or Chronic Heart Failure. Successful long-term management of patients with chronic conditions requires active patient self-management and a proactive involvement of patients in their healthcare and treatment. This calls for a patient-provider partnership within an integrated system of collaborative care, supporting self-management, shared-decision making, collection of patient reported outcome measures, education, and follow-up.
METHODS: ADLIFE follows an outcome-based and patient-centered approach where PROMs represent an especially valuable tool to evaluate the outcomes of the care delivered. We have selected 11 standardized PROMs for evaluating the most recent patients' clinical context, enabling the decision-making process, and personalized care planning. The ADLIFE project implements the "SHARE approach' for enabling shared decision-making via two digital platforms for healthcare professionals and patients. We have successfully integrated PROMs and shared decision-making processes into our digital toolbox, based on an international interoperability standard, namely HL7 FHIR. A usability study was conducted with 3 clinical sites with 20 users in total to gather feedback and to subsequently prioritize updates to the ADLIFE toolbox.
RESULTS: User satisfaction is measured in the QUIS7 questionnaire on a 9-point scale in the following aspects: overall reaction, screen, terminology and tool feedback, learning, multimedia, training material and system capabilities. With all the average scores above 6 in all categories, most respondents have a positive reaction to the ADLIFE PEP platform and find it easy to use. We have identified shortcomings and have prioritized updates to the platform before clinical pilot studies are initiated.
CONCLUSIONS: Having finalized design, implementation, and pre-deployment usability studies, and updated the tool based on further feedback, our patient empowerment mechanisms enabled via PROMs and shared decision-making processes are ready to be piloted in clinal settings. Clinical studies will be conducted based at six healthcare settings across Spain, UK, Germany, Denmark, and Israel.
Within the study data on quality of life and various health and non-health resources and their costs is collected with the help of questionnaires administered at different points in time in different cohorts. Data collection is additional upon data collected in the main CAPITA trial, such as incidence data, mortality estimates, use of some health care resources, vaccine effectiveness and general background (socio-demographic) data.

In a first sub-study of CHO-CAP, the CAPITA participants are asked, via written information distributed shortly after vaccination, to fill in once-only a short questionnaire describing their health status (5 item EQ-5D instrument) and a few additional socio-demographic background data. This is done in order to determine an EQ-5D baseline score (index value for health status) - a prerequisite to match CAP patients and controls later, and as such an inclusion criterion for the two (nested) cohorts that will be followed prospectively.

About 2,000 cases of CAP are expected to occur in the CAPITA cohort in the next two to three years. Assuming a response rate of \~30% for the baseline questionnaire, we will have some 600 CAP cases out of the 2,000 expected patients for whom a baseline EQ-5D score is available. These CAP patients will be asked to participate in a prospective cohort study. Within CHO-CAP, these CAP cases will be followed for up to one year after their CAP episode. For each CAP case included in the CAP cohort, two controls from the baseline population are matched and included in a cohort of controls (non-CAP elderly with similar baseline health status). Controls will also be followed for up to one year. The matches between CAP cases and controls will be made based on age, sex and EQ-5D baseline score. This implies that controls will only be recruited from the group that responded to the baseline measurement of health status shortly after vaccination. For both cohorts, the CAP patients and the matched controls, additional data on health care and non-health care resource use, on health status, using EQ-5D and SF-36 questionnaires, and on selected health outcomes is collected at four contact (at 0, 1, 6 and 12 months) moments within a period of 1 year. This will be done using questionnaires, distributed during a home visit and by post.
FIELD: cosmetics. SUBSTANCE: invention relates to cosmetic compositions comprising in cosmetically acceptable medium copolymer of methacrylic acid and (C 1 -C 4 )--alkylacrylate, amphoteric polymer or cationic polymer with cationic charge density less 1 meq/g, mother-of-pearl addition, and/or dull finishing component and polydialkylsiloxane with terminal trimethylsilyl groups. These compositions are used, in part, for washing keratin materials and/or care for keratin materials, such as hair or skin. Compositions confer softness and provide stability. EFFECT: improved and valuable properties of composition. 44 cl, 1 tbl
Participants who completed Part 1, 2, or 3 and who are amyloid positive (≥24 centiloids) at week 12 of OLE will receive RO7126209 Q4W for an additional 12 weeks, before to switch to Q12W dosing for the remaining 77 weeks in an open-label treatment period. The dose level will depend on the dose level received in Part 1,2, and 3.
The present disclosure provides a system and method for multi-spectral and label-free autofluorescence histochemical on-the-fly virtual staining. The system includes a sample holder, one or more light sources, an imaging device, and a processor device. The sample holder is configured to secure a sample to a movable structure that is movable along at least two dimensions. The one or more light sources are configured to obliquely illuminate the sample to effect excitation of the sample. The imaging device is configured to capture an image of the sample, and the processing device is configured to receive the image of the sample and process the image according to a histochemical virtual staining process. The image comprises an autofluorescence image, and the histochemical virtual staining process comprises subdividing the autofluorescence image into a plurality of regions, globally sampling selected regions of the autofluorescence image, and classifying the autofluorescence image into one of a plurality of real image categories or a pseudo-image category.
Carcinogenesis, mutagenesis and impairment of fertility have not been studied with malathion lotion (0.5% pharmaceutical grade malathion). However, following long-term oral administration of technical grade malathion to rodents via dietary supplementation, increased incidences of hepatocellular neoplastic lesions were observed in B6C3F1 mice dosed for 18 months at malathion doses greater than 1500 mg/kg/day, and in female F344 rats dosed for 2 years at malathion doses greater than 400 mg/kg/day. These tumors occurred only in association with severe hepatic toxicity and chronic suppression of acetylcholinesterase activity, or at doses causing excessive mortality. Based on body surface area, doses at which carcinogenic effects were observed in rodents following life-time exposures to malathion were approximately 14- to 26-fold greater than the maximum dose anticipated in a 10 kg child following a single use of malathion lotion, assuming 100% bioavailability. Actual systemic exposures are expected to be less than 10% of the administered dose.

The malathion of greater than pharmaceutical-grade purity used in malathion lotion has not been tested for genotoxicity. The technical-grade malathion (95% pure) was found to be negative in Salmonella typhimurium, equivocally positive in the mouse lymphoma cell assay, and positive in in vitro chromosomal aberration and sister chromatid exchange assays. Fifteen separate in vitro gene mutation studies with malathion of unknown purity have reported negative results, while three studies reported malathion to be mutagenic in bacterial cells. Both technical grade (94–96.5%) and purified (98-99%) malathion have been reported to cause chromosomal aberrations and sister chromatid exchanges in vitro in human and hamster cell lines. In vivo chromosomal aberration and micronucleus studies of technical- grade malathion are reported to be positive, whereas an in vivo chromosomal aberration study of >99% pure malathion was reported to be negative. Furthermore, mice exposed to malathion in their drinking water for 7 weeks demonstrated no evidence of chromosome damage in bone marrow cells, spermatogonia, or primary spermatocytes. Lack of details makes independent evaluation of the results of these assays impossible. Ashby and Purchase have suggested that impurities may be responsible for some of the observed genetic activity of malathion.

Reproduction studies performed with malathion in rats at doses over 180 fold greater than those anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability) revealed no evidence of impaired fertility.
Parenterally administrable aqueous compositions comprise a compound of general formula <FORM:0948582/A5-A6/1> wherein n is an integer from 1 to 10 solubilized by a two component system of a condensation product of castor oil and ethylene oxide containing from about 20 to about 40 moles. of ethylene oxide per mole. of castor oil, and a water-miscible amide of the formula R-CO-NR1R11 wherein R is a hydrogen atom or a methyl radical, R1 is a hydrogen atom or a methyl or ethyl radical and R11 is a methyl or ethyl radical. Desirably the condensation product is used in amounts of from about 5 to about 25 mg. (preferably about 7 to about 15 mg.) per mg. of the active compound the amount of amide used being from 1.0 p  to 7.5% (V/V) of the total solution (preferably about 3.5 to about 5.5%). Conventional isotonicising agents and preservatives may also be present.  Specification 928,161 is referred to.
1. A pharmaceutical composition comprising: a) an LHRH peptide agonist, an LHRH antagonist or a growth hormone releasing factor peptide as active ingredient; b) nicotinamide; and c) a physiological aqueous solution. 2. The pharmaceutical composition according to claim 1, wherein the active ingredient is an LHRH peptide antagonist. 3. The pharmaceutical composition according to claim 1 or claim 2, wherein the active ingredient is Antide or human GRF. 4. The pharmaceutical composition according to any one of claims 1 to 3, which is lyophilised and reconstitutable and further comprises one or more stabilizing agents. 5. The pharmaceutical composition according to any one of claims 1 to .4, which further comprises propylene glycol. 6. The pharmaceutical composition according to any one of claims 1 to 5, which is suitable for parenteral, oral, nasal or pulmonary administration route. 7. The pharmaceutical composition according to any one of claims 1 to 6, further comprising one or more pharmaceutically acceptable excipients. 8. The pharmaceutical composition according to any one of claims 1 to 7, which is suitable for injections. 9. The pharmaceutical composition according to any one of claims 1 to 8, which has the following composition ranges: antide or hGRF 0.1 - 20.0 mg nicotinamide 10 - 300 mg propylene glycol 0 - 800 mg aqueous phase, q.s. 1.0 ml.